Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of telitacicept for neuromyelitis optica spectrum disorder
CTR20171252Phase 3Terminated
- Sponsor
- RemeGen
- Start
- Jan 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by RemeGen. Started Jan 2018; status: terminated.
02
Drugs
telitacicept
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20171252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171252.